PE20100260A1 - Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol - Google Patents

Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol

Info

Publication number
PE20100260A1
PE20100260A1 PE2009000944A PE2009000944A PE20100260A1 PE 20100260 A1 PE20100260 A1 PE 20100260A1 PE 2009000944 A PE2009000944 A PE 2009000944A PE 2009000944 A PE2009000944 A PE 2009000944A PE 20100260 A1 PE20100260 A1 PE 20100260A1
Authority
PE
Peru
Prior art keywords
methylthi
pyrane
ethoxybenzyl
triol
tetrahydro
Prior art date
Application number
PE2009000944A
Other languages
English (en)
Spanish (es)
Inventor
Paul Susan Margaret De
Anett Perlberg
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PE20100260A1 publication Critical patent/PE20100260A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2009000944A 2008-07-17 2009-07-15 Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol PE20100260A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17

Publications (1)

Publication Number Publication Date
PE20100260A1 true PE20100260A1 (es) 2010-04-16

Family

ID=41137707

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000944A PE20100260A1 (es) 2008-07-17 2009-07-15 Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol

Country Status (28)

Country Link
US (2) US8217156B2 (enExample)
EP (1) EP2332947B1 (enExample)
JP (2) JP2011528366A (enExample)
KR (2) KR20170010069A (enExample)
CN (2) CN102112483A (enExample)
AR (1) AR072807A1 (enExample)
AU (1) AU2009270973B2 (enExample)
CA (1) CA2730931A1 (enExample)
CL (1) CL2009001595A1 (enExample)
CO (1) CO6351797A2 (enExample)
DK (1) DK2332947T3 (enExample)
ES (1) ES2656357T3 (enExample)
HK (1) HK1243713A1 (enExample)
HU (1) HUE035400T2 (enExample)
IL (1) IL210269A (enExample)
MX (1) MX2011000503A (enExample)
NO (1) NO2332947T3 (enExample)
NZ (1) NZ590184A (enExample)
PE (1) PE20100260A1 (enExample)
PL (1) PL2332947T3 (enExample)
PT (1) PT2332947T (enExample)
RU (1) RU2505543C2 (enExample)
SG (1) SG185317A1 (enExample)
TW (1) TWI472521B (enExample)
UA (1) UA106048C2 (enExample)
UY (1) UY31992A (enExample)
WO (1) WO2010009197A1 (enExample)
ZA (1) ZA201100175B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
EA017411B1 (ru) 2007-07-26 2012-12-28 Лексикон Фармасьютикалз, Инк. Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3489226B1 (en) * 2012-11-20 2021-02-17 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
WO2015069441A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
EP3330275A4 (en) 2015-07-30 2018-12-05 Microbial Chemistry Research Foundation Novel aminoglycoside antibiotic effective against multidrug-resistant bacteria
CN109195980B (zh) * 2016-05-25 2022-05-17 苏州科睿思制药有限公司 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
WO2018067805A1 (en) 2016-10-06 2018-04-12 Teva Pharmaceutical Industries Ltd. Solid state forms of sotagliflozin
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
JP2021520394A (ja) 2018-04-17 2021-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、処置方法及びその使用
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
EP3856714A1 (en) * 2018-09-26 2021-08-04 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
MA54051A (fr) 2018-10-29 2022-02-09 Boehringer Ingelheim Int Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations
EP3873599B1 (en) 2018-10-29 2023-09-27 Boehringer Ingelheim International GmbH Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN109824687B (zh) * 2019-03-26 2022-03-22 上海凌凯医药科技有限公司 呋喃木糖衍生物的新合成方法
EP3957634A4 (en) * 2019-07-05 2022-08-31 Shangdong Danhong Pharmaceutical Co., Ltd. CRYSTALLINE FORM OF SGLT INHIBITOR AND ITS APPLICATION
EP3771480A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
EP3771718A1 (en) * 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Process for preparing the crystalline form ii of sotagliflozin
US20240100013A1 (en) 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
WO2022155303A1 (en) 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
WO2025072413A1 (en) 2023-09-28 2025-04-03 Lexicon Pharmaceuticals, Inc. Methods of treating type 1 diabetes and kidney disease
WO2025076165A1 (en) 2023-10-06 2025-04-10 Lexicon Pharmaceuticals, Inc. Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy
PL446852A1 (pl) * 2023-11-27 2025-06-02 Politechnika Rzeszowska im. Ignacego Łukasiewicza Układ doprowadzający wodę do pralki

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE602006009772D1 (de) 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
CN1820858A (zh) * 2006-03-10 2006-08-23 广西中医学院制药厂 多相物料喷雾方法及装置
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
EA017411B1 (ru) * 2007-07-26 2012-12-28 Лексикон Фармасьютикалз, Инк. Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
EP2332947A1 (en) 2011-06-15
JP6283337B2 (ja) 2018-02-21
MX2011000503A (es) 2011-03-01
HK1243713A1 (zh) 2018-07-20
CN102112483A (zh) 2011-06-29
WO2010009197A1 (en) 2010-01-21
RU2505543C2 (ru) 2014-01-27
US20130165395A1 (en) 2013-06-27
US8217156B2 (en) 2012-07-10
UA106048C2 (uk) 2014-07-25
KR20110031196A (ko) 2011-03-24
TWI472521B (zh) 2015-02-11
CL2009001595A1 (es) 2010-07-19
ES2656357T3 (es) 2018-02-26
UY31992A (es) 2010-02-26
BRPI0916191A2 (pt) 2017-08-29
NZ590184A (en) 2012-09-28
US20100016422A1 (en) 2010-01-21
IL210269A0 (en) 2011-03-31
JP2016041701A (ja) 2016-03-31
RU2011105797A (ru) 2012-08-27
PL2332947T3 (pl) 2018-04-30
AU2009270973B2 (en) 2014-01-30
ZA201100175B (en) 2012-03-28
SG185317A1 (en) 2012-11-29
PT2332947T (pt) 2018-02-06
KR20170010069A (ko) 2017-01-25
JP2011528366A (ja) 2011-11-17
DK2332947T3 (da) 2018-01-29
CO6351797A2 (es) 2011-12-20
NO2332947T3 (enExample) 2018-03-31
TW201006808A (en) 2010-02-16
KR101707246B1 (ko) 2017-02-15
CA2730931A1 (en) 2010-01-21
AU2009270973A1 (en) 2010-01-21
HUE035400T2 (en) 2018-05-02
IL210269A (en) 2015-06-30
CN107629097A (zh) 2018-01-26
EP2332947B1 (en) 2017-11-01
US9067962B2 (en) 2015-06-30
AR072807A1 (es) 2010-09-22

Similar Documents

Publication Publication Date Title
PE20100260A1 (es) Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol
CL2011001757A1 (es) Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico.
PE20140983A1 (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
BRPI0717125B8 (pt) Composto derivado de ftalazinona como forma cristalina a, métodos para obter o mesmo e usos terapêuticos do dito composto
WO2015028969A3 (en) Transduction buffer
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
MX374694B (es) USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS.
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
CL2007003713A1 (es) Compuestos derivados de 2-amino-4-oxo-3,5-dihidroimidazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir una patologia relacionada con abeta, tales como alzheimer, parkinson, sindrome de down, entre otras
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
HUE041364T2 (hu) (2S,3R,4R,5S,6R)-2-(4-klór-3-(4-etoxibenzil)fenil)-6- (metiltio)tetrahidro-2H-pirán-3,4,5-triolt tartalmazó készítmények
PH12018500071A1 (en) Plinabulin compositions
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
PE20131371A1 (es) Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
CL2013001221A1 (es) Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto.
CL2008002045A1 (es) Forma cristalina b de 3-(difluorometil)-1-metil-n-(3',4',5'triofluoro (1,1'-bifenil)-2-il)-h-pirazol-4-carboxamida; procedimiento de preparación de dicha forma cristalina; agente fitoprotector que la contiene y método para combatir el crecimiento de plantas no deseadas.
PE20141528A1 (es) Composicion fungicida agricola u horticola y procedimiento para controlar patogeno de plantas
CL2014000895A1 (es) Compuestos derivados de {2-cloro-4-[hidroxi(cicloalquil/heterociclil)]amino]fenil}acetonitrilo, moduladores selectivos del receptor androgeno; composicion farmaceutica; composicion farmceutica que comprende una forma cristalina; y su uso en el tratamiento de la atrofia muscular
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CL2012001290A1 (es) Compuestos derivados de canfenos arilados, estimulantes selectivos de receptores cb2; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad, trastorno o afeccion seleccionada de inflamacion, dolor, alergia, diabetes, ateroesclerosis, artritis y emesis, entre otras.
BRPI0810560A2 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida.

Legal Events

Date Code Title Description
FC Refusal